Boston Scientific Corp. shares fall 3.42 percent, lagging sector rivals
Updated
Updated · MarketWatch · Apr 27
Boston Scientific Corp. shares fall 3.42 percent, lagging sector rivals
14 articles · Updated · MarketWatch · Apr 27
The stock closed at $59.95 on Monday, marking its second consecutive day of losses and trading 45.25% below its 52-week high of $109.50.
Boston Scientific underperformed competitors such as Abbott Laboratories, which rose 1.83%, and Stryker Corp., which gained 0.46%, during a mixed session for major indices.
Trading volume for Boston Scientific reached 17.5 million, surpassing its 50-day average, as the S&P 500 edged up and the Dow Jones slipped slightly.
Why isn't the groundbreaking CHAMPION-AF trial data preventing the stock's continued freefall?
Is Boston Scientific's dominance in electrophysiology officially over as competitors gain ground?
Are tougher FDA regulations the hidden threat that could derail Boston Scientific’s future product pipeline?
Will the massive $14.5B Penumbra acquisition save Boston Scientific or sink it with more debt?
Amid fraud lawsuits and a CEO stock sale, can investors still trust management's turnaround strategy?